S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in

Hologic Stock Forecast, Price & News

-2.01 (-2.70 %)
(As of 01/27/2021 12:00 AM ET)
Today's Range
Now: $72.51
50-Day Range
MA: $75.45
52-Week Range
Now: $72.51
Volume3.13 million shs
Average Volume1.74 million shs
Market Capitalization$18.68 billion
P/E Ratio17.26
Dividend YieldN/A
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Hologic logo


Overall MarketRank

1.85 out of 5 stars

Medical Sector

115th out of 1,926 stocks

X-Ray Apparatus & Tubes Industry

1st out of 3 stocks

Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:HOLX
Year FoundedN/A



Sales & Book Value

Annual Sales$3.78 billion
Cash Flow$5.14 per share
Book Value$10.45 per share


Net Income$1.12 billion


Market Cap$18.68 billion
Next Earnings DateN/A
-2.01 (-2.70 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hologic (NASDAQ:HOLX) Frequently Asked Questions

How has Hologic's stock price been impacted by COVID-19 (Coronavirus)?

Hologic's stock was trading at $43.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HOLX shares have increased by 65.6% and is now trading at $72.51.
View which stocks have been most impacted by COVID-19

Is Hologic a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Hologic stock.
View analyst ratings for Hologic
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Hologic?

Wall Street analysts have given Hologic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hologic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Steve MacMillan's approval rating as Hologic's CEO?

283 employees have rated Hologic CEO Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among Hologic's employees.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings data on Wednesday, January, 27th. The medical equipment provider reported $2.86 earnings per share for the quarter, beating the consensus estimate of $2.17 by $0.69. The medical equipment provider had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.39 billion. Hologic had a trailing twelve-month return on equity of 45.24% and a net margin of 29.53%. The business's revenue for the quarter was up 89.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.61 EPS.
View Hologic's earnings history

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its second quarter earnings guidance on Wednesday, January, 27th. The company provided EPS guidance of $2.53-2.68 for the period, compared to the Thomson Reuters consensus estimate of $1.99. The company issued revenue guidance of $1.5-1.56 billion, compared to the consensus revenue estimate of $1.35 billion.

What price target have analysts set for HOLX?

13 Wall Street analysts have issued 1 year price objectives for Hologic's shares. Their forecasts range from $43.00 to $100.00. On average, they expect Hologic's share price to reach $79.56 in the next year. This suggests a possible upside of 9.7% from the stock's current price.
View analysts' price targets for Hologic
or view Wall Street analyst' top-rated stocks.

Who are some of Hologic's key competitors?

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), The Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

Who are Hologic's key executives?

Hologic's management team includes the following people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 57, Pay $3.27M)
  • Ms. Karleen M. Oberton, Chief Financial Officer (Age 51, Pay $1.06M)
  • Mr. John M. Griffin, Gen. Counsel (Age 60, Pay $1.12M)
  • Mr. Kevin R. Thornal, Division Pres of Diagnostic Solutions (Age 47, Pay $1.89M)
  • Mr. Peter J. Valenti III, Sr. Advisor to Chief Exec. Officer (Age 58, Pay $1.19M)
  • Dr. Jay A. Stein, Co-Founder, Chairman Emeritus, CTO & Sr. VP (Age 78)
  • Mr. Michael J. Watts, VP of Investor Relations & Corp. Communications
  • Ms. Allison P. Bebo, Sr. VP of HR (Age 52)
  • Mr. Jan Verstreken, Group Pres of International
  • Mr. Sanjay Prabhakaran, Regional Pres of Asia Pacific

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.37%), Frontier Capital Management Co. LLC (0.22%), Trinity Street Asset Management LLP (0.21%), Robeco Institutional Asset Management B.V. (0.15%), Wedge Capital Management L L P NC (0.15%) and New York State Teachers Retirement System (0.15%). Company insiders that own Hologic stock include Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Kevin R Thornal, Peter J Valenti III, Sally Crawford and Stephen P Macmillan.
View institutional ownership trends for Hologic

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Frontier Capital Management Co. LLC, Wedge Capital Management L L P NC, Gateway Investment Advisers LLC, Davis R M Inc., Raymond James Trust N.A., LaFleur & Godfrey LLC, and Highland Capital Management LLC. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, John M Griffin, Kevin R Thornal, Peter J Valenti III, Sally Crawford, and Stephen P Macmillan.
View insider buying and selling activity for Hologic
or view top insider-selling stocks.

Which major investors are buying Hologic stock?

HOLX stock was bought by a variety of institutional investors in the last quarter, including Trinity Street Asset Management LLP, Candriam Luxembourg S.C.A., DNB Asset Management AS, Nisa Investment Advisors LLC, Patten & Patten Inc. TN, New York State Teachers Retirement System, Nia Impact Advisors LLC, and McGuire Investment Group LLC.
View insider buying and selling activity for Hologic
or or view top insider-buying stocks.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $72.51.

How big of a company is Hologic?

Hologic has a market capitalization of $18.68 billion and generates $3.78 billion in revenue each year. The medical equipment provider earns $1.12 billion in net income (profit) each year or $3.98 on an earnings per share basis. Hologic employs 5,814 workers across the globe.

What is Hologic's official website?

The official website for Hologic is www.hologic.com.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.